A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma

被引：0
|
作者：
Campos, S. [1 ]
Penson, R. [2 ]
Berlin, S. [3 ]
Matulonis, U. [3 ]
Horowitz, N. [3 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [1] A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
    Campos, Susana M.
    Penson, Richard T.
    Matulonis, Ursula
    Horowitz, Neil S.
    Whalen, Christin
    Pereira, Lauren
    Tyburski, Karin
    Roche, Maria
    Szymonifka, Jackie
    Berlin, Suzanne
    GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 215 - 220
  • [2] A Phase II trial of oral capecitabine in patients with platinum and taxane refractory ovarian, fallopian tube, or peritoneal cancer
    Wolf, Judith K.
    Bodurka, Diane C.
    Verschraegen, Claire
    Sun, Charlotte C.
    Branham, Donna
    Jenkins, Alfred D.
    Atkinson, Neely
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2006, 102 (03) : 468 - 474
  • [3] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
    Taylor, Sarah E.
    Chu, Tianjiao
    Elvin, Julia A.
    Edwards, Robert P.
    Zorn, Kristin K.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 32 - 37
  • [5] Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Sabbatini, P
    Aghajanian, C
    Dizon, D
    Anderson, S
    Dupont, J
    Brown, JV
    Peters, WA
    Jacobs, A
    Mehdi, A
    Rivkin, S
    Eisenfeld, AJ
    Spriggs, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4523 - 4531
  • [6] A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185
    Biagi, J. J.
    Oza, A. M.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma
    Piura, B
    Rabinovich, A
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2004, 25 (04) : 449 - 452
  • [8] Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer
    Herzog, Thomas J.
    Powell, Matthew A.
    Rader, Janet S.
    Gibb, Randall K.
    Lippmann, Lynne
    Coleman, Robert L.
    Mutch, David G.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 467 - 473
  • [9] Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan - A phase II trial of the Puget Sound Oncology Consortium
    Goff, Barbara A.
    Holmberg, Leona A.
    Veljovich, Dan
    Kurland, Brenda F.
    GYNECOLOGIC ONCOLOGY, 2008, 110 (02) : 146 - 151
  • [10] A phase II trial of pembrolizumab in combinationwith bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Zsiros, E.
    Frederick, P. J.
    Akers, S. N.
    Attwood, K.
    Wang, K.
    Lele, S. B.
    Odunsi, K.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
12345